Trichomonas vaginalis Prevention and Screening: Condoms, Guidelines, and Health Equity

  1. What Prevention Can and Cannot Do
  2. Condom Effectiveness
  3. Mutual Monogamy
  4. Routine Screening Guidelines
  5. USPSTF 2020: Behavioral Counseling
  6. Groups the Guideline Names for Screening
  7. PrEP and Other STIs
  8. Healthcare Disparities and Access
  9. Post-Exposure Management After Sexual Assault
  10. Vaccine Research
  11. Key Research Papers
  12. Connections

What Prevention Can and Cannot Do

The 2021 CDC guideline states that among persons who are sexually active, the best way to prevent genital trichomoniasis is through consistent and correct use of condoms (external or internal) (CDC 2021, PubMed PMID: 34292926). It also states that partners of men who have been circumcised might have a somewhat reduced risk for T. vaginalis infection, and that douching is not recommended because it might increase the risk for vaginal infections, including trichomoniasis (CDC 2021, PubMed PMID: 34292926). Vaccine research is at an early stage (see Vaccine Research below).

Transmission: the guideline states that T. vaginalis is readily passed between sex partners during penile-vaginal sex, and through infected vaginal fluids or fomites among women who have sex with women (CDC 2021, PubMed PMID: 34292926). A review states that humans are its only known host and that it is transmitted primarily by sexual intercourse; it does not appear to have a cyst form and does not survive well in the external environment, although it can survive outside the human body in a wet environment for more than three hours. While thought to be rare, evidence of non-sexual transmission via fomites and possibly water has been described (Kissinger 2015, PubMed PMID: 26242185).

Why infection goes unnoticed: the guideline states that most people with trichomoniasis (70%-85%) have minimal or no genital symptoms and that untreated infections might last from months to years (CDC 2021, PubMed PMID: 34292926). It states that treatment reduces symptoms and signs of infection and might reduce transmission (CDC 2021, PubMed PMID: 34292926).

Condom Effectiveness

The guideline states that studies demonstrate consistent condom use reduces the risk for STIs including chlamydia, gonorrhea, hepatitis B and trichomoniasis (CDC 2021, PubMed PMID: 34292926). One study it cites followed 929 patients attending STI clinics for up to 6 months, with urine NAAT for chlamydia, gonorrhea and trichomoniasis at baseline, 3 and 6 months and electronic daily diaries for each act of penile-vaginal intercourse. Consistent condom use alone was not significantly associated with STI incidence (estimated odds ratio 0.75, 95% CI 0.43-1.30), but participants who used condoms both correctly and consistently had an estimated 59% lower odds of acquiring an STI (estimated odds ratio 0.41, 95% CI 0.19-0.90) (Crosby 2012, PubMed PMID: 23002192). The abstract reports these figures for the three infections combined, not for trichomoniasis alone.

Internal (female) condoms: the guideline states that they can provide protection from acquisition and transmission of STIs, although data are limited; that they cost more than external condoms; and that they offer the advantage of being controlled by the receptive partner (CDC 2021, PubMed PMID: 34292926).

Diaphragms: the guideline states that in observational studies diaphragm use has been demonstrated to protect against cervical gonorrhea, chlamydia and trichomoniasis, but that a trial of a diaphragm plus lubricant among women in Africa found no additional protection against HIV compared with male condoms alone, and that diaphragms should not be relied on as the sole source of protection against HIV and other STIs (CDC 2021, PubMed PMID: 34292926).

Barriers between women: the guideline notes that, in the studies it reviewed, use of barrier protection with female partners (gloves during digital-genital sex, external condoms with sex toys, and latex or plastic barriers, also known as dental dams, for oral-genital sex) was infrequent (CDC 2021, PubMed PMID: 34292926).

Nonoxynol-9: the guideline states that condoms with nonoxynol-9 are no more effective than condoms without it, and that nonoxynol-9 alone or in a condom is not recommended for STI and HIV prevention (CDC 2021, PubMed PMID: 34292926).

Mutual Monogamy

Because the guideline states that most infections cause minimal or no symptoms and that untreated infections might last from months to years (CDC 2021, PubMed PMID: 34292926), a new diagnosis in one partner of a couple does not by itself show when the infection was acquired or who was the source. A review gives infection as possibly persisting for months or even years in women, but generally for less than 10 days in men (Kissinger 2015, PubMed PMID: 26242185).

The guideline states that male partners of women with trichomoniasis are likely to have infection and that concurrent treatment of all sex partners is vital for preventing reinfections (CDC 2021, PubMed PMID: 34292926). Among the prevention measures it lists for counseling are limiting the number of sex partners and correct and consistent use of condoms (CDC 2021, PubMed PMID: 34292926). Partner treatment is covered on the Partner Treatment and Reinfection page.

Routine Screening Guidelines

The guideline states that trichomoniasis is not a reportable disease and that no recommendations are available for general screening for T. vaginalis (CDC 2021, PubMed PMID: 34292926). This differs from chlamydia, for which it recommends annual screening of all sexually active women aged under 25 years, and screening of older women at increased risk (CDC 2021, PubMed PMID: 34292926).

What the guideline does say about trichomoniasis testing and screening: diagnostic testing should be performed for women seeking care for vaginal discharge; annual screening might be considered for persons receiving care in high-prevalence settings (for example, STD clinics and correctional facilities) and for asymptomatic women at high risk for infection (for example, multiple sex partners, transactional sex, drug misuse, or a history of STIs or incarceration). It adds that data are lacking on whether screening and treatment for asymptomatic trichomoniasis in high-prevalence settings for women at high risk can reduce adverse health events and health disparities or reduce community infection burden, and that decisions about screening can be guided by the local epidemiology of T. vaginalis infection (CDC 2021, PubMed PMID: 34292926).

Adolescents and young adults: the guideline states that local disease prevalence can help guide decisions about screening for T. vaginalis, especially among adolescent females in certain areas, and that routine screening of asymptomatic adolescents and young adults for certain STIs, including trichomoniasis, is not typically recommended (CDC 2021, PubMed PMID: 34292926).

Extragenital sites: the guideline states that extragenital infection is possible but highly uncommon, that the efficacy, benefit and cost-effectiveness of extragenital screening are unknown, that no tests are FDA cleared for extragenital testing, and that rectal and oral testing for T. vaginalis is therefore not recommended (CDC 2021, PubMed PMID: 34292926).

Prevalence in clinic settings: the guideline reports a prevalence of 14.6% among women attending nine geographically diverse STD clinics, 27% among women and 9.8% among men in a study of STD clinic attendees in Birmingham, Alabama, and a four times higher rate of infection in symptomatic than in asymptomatic women (26% versus 6.5%) (CDC 2021, PubMed PMID: 34292926).

USPSTF 2020: Behavioral Counseling

The US Preventive Services Task Force's 2020 statement on sexually transmitted infections concerns behavioral counseling, not screening for trichomoniasis. It recommends behavioral counseling for all sexually active adolescents and for adults at increased risk for STIs (a B recommendation), concluding with moderate certainty that behavioral counseling interventions reduce the likelihood of acquiring STIs in sexually active adolescents and in adults at increased risk, including, for example, those who have a current STI, do not use condoms, or have multiple partners (USPSTF 2020, PubMed PMID: 32809008).

The evidence review behind it included 37 randomized trials and 2 nonrandomized controlled studies (N = 65,888) recruited from US primary care, mostly of heterosexual adolescents and young adults, females, and racial and ethnic minorities at increased risk. In 19 trials reporting STI diagnoses, counseling was associated with reduced STI incidence (odds ratio 0.66, 95% CI 0.54-0.81), and absolute differences ranged from 19% fewer to 4% more people acquiring an STI, depending on baseline risk and intervention effectiveness. Sessions lasting more than 2 hours were associated with larger reductions; evidence was limited on whether reductions persisted beyond 1 year; no harms were identified in the 7 studies reporting adverse outcomes (Henderson 2020, doi:10.1001/jama.2020.10371).

The CDC guideline likewise states that the USPSTF recommends intensive behavioral counseling for all sexually active adolescents and for adults at increased risk for STIs and HIV (CDC 2021, PubMed PMID: 34292926). Its own trichomoniasis screening statements are described in the section above.

Groups the Guideline Names for Screening

The guideline does not recommend general screening for trichomoniasis (CDC 2021, PubMed PMID: 34292926), but it names several groups:

Women with HIV: the guideline states that up to 53% of women with HIV have T. vaginalis infection, that the infection among these women is substantially associated with pelvic inflammatory disease, and that routine screening and prompt treatment are recommended for all women with HIV, at entry to care and then at least annually (CDC 2021, PubMed PMID: 34292926). Among women who are not virally suppressed, it states, treatment is associated with decreases in genital tract HIV viral load and viral shedding (CDC 2021, PubMed PMID: 34292926); in one New Orleans HIV clinic study, women effectively treated for T. vaginalis were less likely to shed HIV vaginally 3 months after treatment than at baseline (relative risk 0.34) (Kissinger 2009, PubMed PMID: 19008776). In a retrospective cohort of 1,578 women with HIV followed from 1990 to 2000, 30.2% had T. vaginalis at least once, it was more common than chlamydia, gonorrhea, genital warts or syphilis, and it was not associated with immune status or protease inhibitor use (Magnus 2003, PubMed PMID: 14603092).

Incarcerated women: the guideline gives rates of 9%-32% among incarcerated women and states that women with a history of incarceration are two to five times more likely to have T. vaginalis (CDC 2021, PubMed PMID: 34292926). Its correctional-facility section states that females aged 35 years or younger housed in correctional facilities should be screened for trichomonas at intake, offered as opt-out screening (CDC 2021, PubMed PMID: 34292926).

People attending STD clinics and other high-prevalence settings: the guideline states that annual screening might be considered, with decisions guided by local epidemiology (CDC 2021, PubMed PMID: 34292926) (see Routine Screening Guidelines above).

Pregnant women: the guideline states that evidence does not support routine screening for T. vaginalis among asymptomatic pregnant women, that women who report symptoms should be evaluated and treated, and that symptomatic pregnant women, regardless of pregnancy stage, should be tested and treated (CDC 2021, PubMed PMID: 34292926). For pregnant women with HIV, it recommends screening at the first prenatal visit and prompt treatment as needed, because T. vaginalis infection is a risk factor for vertical transmission of HIV (CDC 2021, PubMed PMID: 34292926). A 2021 meta-analysis of 19 studies associated trichomoniasis in pregnancy with preterm delivery (odds ratio 1.27; 95% CI 1.08-1.50), prelabour rupture of membranes (1.87; 1.53-2.29) and low birthweight (2.12; 1.15-3.91), and its authors wrote that rigorous studies are needed to determine the impact of universal screening and treatment during pregnancy (Van Gerwen 2021, PubMed PMID: 34036690).

Women who have sex with women: the guideline states that trichomonas is a relatively common infection among women who have sex with women, with prevalence higher than for chlamydia or gonorrhea, and that direct transmission between female partners has been demonstrated (CDC 2021, PubMed PMID: 34292926).

Transgender and nonbinary people: the guideline's section on transgender and gender diverse persons calls for a comprehensive sexual history, including a discussion of STI screening; it gives no trichomoniasis-specific screening schedule for this group (CDC 2021, PubMed PMID: 34292926).

Women with bacterial vaginosis: the guideline states that women with bacterial vaginosis are at higher risk for T. vaginalis (CDC 2021, PubMed PMID: 34292926). A 2016 review discusses competing hypotheses on how bacterial vaginosis develops (Muzny 2016, PubMed PMID: 27449868).

PrEP and Other STIs

HIV pre-exposure prophylaxis (PrEP) uses antiretroviral medication. The guideline describes daily oral PrEP with a fixed-dose combination of emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide as demonstrating safety and a substantial reduction in the rate of HIV acquisition among men who have sex with men, and states that high adherence was strongly associated with protection from HIV infection (CDC 2021, PubMed PMID: 34292926).

The guideline states that clinical practice guidelines recommend STI screening for persons taking PrEP because increased rates of STI acquisition have been described, and that sexually active adults and adolescents should be screened for STIs in accordance with recommendations (CDC 2021, PubMed PMID: 34292926). It also states that contraceptive methods that are not mechanical barriers offer no protection against HIV or other STIs, and lists PrEP, postexposure prophylaxis, limiting the number of sex partners, and correct and consistent use of condoms among the prevention measures for counseling women who use contraceptive methods other than condoms (CDC 2021, PubMed PMID: 34292926).

Healthcare Disparities and Access

The guideline gives US population-based prevalence of 2.1% among females and 0.5% among males, highest among Black females (9.6%) and Black males (3.6%), compared with non-Hispanic White women (0.8%) and Hispanic women (1.4%); unlike chlamydia and gonorrhea, prevalence is as high among women older than 24 as among younger women (CDC 2021, PubMed PMID: 34292926).

An earlier national survey (NHANES 2001-2004), testing self-collected vaginal swabs from 3,754 women aged 14-49 by PCR, found a prevalence of 3.1% overall, 1.3% among non-Hispanic white women, 1.8% among Mexican American women and 13.3% among non-Hispanic Black women, which the authors describe as 10.3 times higher than among non-Hispanic white and Mexican American women. Factors that remained associated with infection in multivariable analysis were non-Hispanic Black race/ethnicity, being born in the United States, a greater number of lifetime sex partners, increasing age, lower educational level, poverty and douching. The authors concluded that optimal prevention and control strategies should be explored as a means of closing the racial disparity gaps (Sutton 2007, PubMed PMID: 17968828).

The guideline lists having two or more sex partners during the previous year, having less than a high school education, and living below the national poverty level as risk factors (CDC 2021, PubMed PMID: 34292926). On screening and disparities, it states that data are lacking on whether screening and treatment for asymptomatic trichomoniasis in high-prevalence settings for women at high risk can reduce adverse health events and health disparities (CDC 2021, PubMed PMID: 34292926).

Tests differ in cost and sensitivity: the guideline describes wet-mount microscopy as inexpensive and done at the point of care but with low sensitivity (44%-68%) compared with culture, and NAATs as highly sensitive, detecting more infections than wet mount among women (CDC 2021, PubMed PMID: 34292926).

Post-Exposure Management After Sexual Assault

The guideline states that trichomoniasis, bacterial vaginosis, gonorrhea and chlamydia are the most frequently diagnosed infections among women who have been sexually assaulted, that these conditions are prevalent in the population, and that detecting them after an assault does not necessarily imply acquisition during the assault (CDC 2021, PubMed PMID: 34292926).

Testing: the guideline states that decisions about testing at the initial examination are made on an individual basis, and that females should be offered NAAT testing for T. vaginalis from a urine or vaginal specimen, alongside NAATs for chlamydia and gonorrhea at sites of penetration or attempted penetration and serum testing for HIV, hepatitis B and syphilis (CDC 2021, PubMed PMID: 34292926).

Presumptive treatment: because compliance with follow-up visits is poor among survivors, the guideline recommends routine presumptive treatment, including an empiric antimicrobial regimen for chlamydia, gonorrhea and trichomonas for women. Its recommended regimen for adolescent and adult female survivors is ceftriaxone 500 mg intramuscularly in a single dose (1 g for persons weighing 150 kg or more), plus doxycycline 100 mg orally twice daily for 7 days, plus metronidazole 500 mg orally twice daily for 7 days; for male survivors it is ceftriaxone plus doxycycline. It states that the efficacy of these regimens in preventing infections after sexual assault has not been evaluated and that gastrointestinal side effects can occur with this combination (CDC 2021, PubMed PMID: 34292926).

Other elements: the guideline lists emergency contraception when the assault could result in pregnancy, postexposure hepatitis B vaccination, HPV vaccination for survivors aged 9-26 years who are unvaccinated or incompletely vaccinated, and HIV postexposure prophylaxis decided case by case according to risk (CDC 2021, PubMed PMID: 34292926).

Follow-up: if initial testing was performed, the guideline describes a follow-up evaluation within 1 week; if initial tests are negative and treatment was not provided, examination for STIs can be repeated 1-2 weeks after the assault; for survivors treated at the initial visit, posttreatment testing only if symptoms are reported (CDC 2021, PubMed PMID: 34292926). It states that examinations of survivors should be conducted by an experienced clinician in a way that minimizes further trauma (CDC 2021, PubMed PMID: 34292926).

Vaccine Research

A 2010 review argued that a T. vaginalis vaccine could reduce the human, medical and societal costs of trichomoniasis, noting that infection is often asymptomatic and goes untreated, creating reservoirs that allow it to spread in the community (Cudmore 2010, PubMed PMID: 20701891). Vaccine candidates described in 2024 and 2025 were designed by computer (immunoinformatics); the 2025 authors state that experimental validation through laboratory and animal studies is necessary to confirm immunogenicity and protective efficacy (Ikram 2025, PubMed PMID: 40779085), and the 2024 authors describe their design as a candidate for such studies (Ghasemi Nezhad 2024, PubMed PMID: 38556882). A 2004 review of metronidazole-resistant infection also summarizes vaccine candidates (Cudmore 2004, PubMed PMID: 15489348).

Biology relevant to vaccine design: the draft genome sequence describes an approximately 160-megabase genome, about two-thirds of it repeats and transposable elements, with amplification of specific gene families implicated in pathogenesis (Carlton 2007, PubMed PMID: 17218520). A 2004 review notes that the immunology of a related organism, Tritrichomonas foetus, which causes disease in cattle, has been investigated to some extent, but that more work is needed for the human parasite (Schwebke 2004, PubMed PMID: 15489349).

Repeat infection after treatment is common, at 5-31% in the studies one review cites (Kissinger 2015, PubMed PMID: 26242185). The guideline estimates the number of persons affected in the United States at approximately 2.6 million, a figure corrected from 3.7 million by a 2023 erratum (CDC 2021, PubMed PMID: 34292926; 2023 erratum, PubMed PMID: 36701253).

Key Research Papers

  1. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. — PubMed PMID: 34292926
  2. Henderson JT, Senger CA, Henninger M, et al. Behavioral counseling interventions to prevent sexually transmitted infections: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2020;324(7):682-699. — doi:10.1001/jama.2020.10371
  3. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis. 2007;45(10):1319-1326. — PubMed PMID: 17968828
  4. Van Gerwen OT, Craig-Kuhn MC, Jones AT, et al. Trichomoniasis and adverse birth outcomes: a systematic review and meta-analysis. BJOG. 2021;128(12):1907-1915. — PubMed PMID: 34036690
  5. Dize L, West SK, Williams JA, et al. Comparison of the Aptima Trichomonas vaginalis assay and culture for the detection of T. vaginalis in male and female genitourinary specimens. Sex Transm Infect. 2013;89(5):395-399. — Search PubMed — Note: no record matching this citation was found in PubMed or Crossref (checked October 2026); nothing on this page relies on it.
  6. Muzny CA, Schwebke JR. Pathogenesis of Bacterial Vaginosis: Discussion of Current Hypotheses. J Infect Dis. 2016;214(Suppl 1):S1-S5. — PubMed PMID: 27449868
  7. Magnus M, Clark R, Myers L, Farley T, Kissinger PJ. Trichomonas vaginalis among HIV-infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis. 2003;30(11):839-843. — PubMed PMID: 14603092
  8. Wendel KA, Workowski KA. Trichomoniasis: challenges to appropriate management. Clin Infect Dis. 2007;44(Suppl 3):S123-S129. — PubMed PMID: 17342665
  9. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis. 2009;36(1):11-16. — PubMed PMID: 19008776
  10. Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev. 2004;17(4):794-803. — PubMed PMID: 15489349
  11. US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, et al. Behavioral counseling interventions to prevent sexually transmitted infections: US Preventive Services Task Force recommendation statement. JAMA. 2020;324(7):674-681. — PubMed PMID: 32809008
  12. Crosby RA, Charnigo RA, Weathers C, Caliendo AM, Shrier LA. Condom effectiveness against non-viral sexually transmitted infections: a prospective study using electronic daily diaries. Sex Transm Infect. 2012;88(7):484-489. — PubMed PMID: 23002192
  13. Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis. 2015;15:307. — PubMed PMID: 26242185
  14. Cudmore SL, Delgaty KL, Hayward-McClelland SF, Petrin DP, Garber GE. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis. Clin Microbiol Rev. 2004;17(4):783-793. — PubMed PMID: 15489348
  15. Cudmore SL, Garber GE. Prevention or treatment: the benefits of Trichomonas vaginalis vaccine. J Infect Public Health. 2010;3(2):47-53. — PubMed PMID: 20701891
  16. Ghasemi Nezhad F, Karmostaji A, Sarkoohi P, et al. Introduction of protein vaccine candidate based on AP65, AP33, and α-actinin proteins against Trichomonas vaginalis parasite: an immunoinformatics design. Parasit Vectors. 2024;17(1):165. — PubMed PMID: 38556882
  17. Ikram E, Yavas C, Akcali N, et al. In silico identification of antigenic peptides and multi-epitope vaccine design against Trichomonas vaginalis. Acta Parasitol. 2025;70(4):174. — PubMed PMID: 40779085
  18. Carlton JM, Hirt RP, Silva JC, et al. Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis. Science. 2007;315(5809):207-212. — PubMed PMID: 17218520
  19. Erratum: Vol. 70, No. RR-4. MMWR Morb Mortal Wkly Rep. 2023;72(4):107-108. — PubMed PMID: 36701253

Back to Table of Contents

Connections